Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Assets (2016 - 2025)

Zevra Therapeutics' Non-Current Assets history spans 11 years, with the latest figure at $61.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 360.63% year-over-year to $61.7 million; the TTM value through Dec 2025 reached $228.8 million, up 1607.27%, while the annual FY2025 figure was $61.7 million, 360.63% up from the prior year.
  • Non-Current Assets reached $61.7 million in Q4 2025 per ZVRA's latest filing, up from $45.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $106.6 million in Q1 2023 to a low of -$87.9 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $28.0 million, with a median of $19.1 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: tumbled 3458.6% in 2022, then surged 3894.12% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $17.9 million in 2021, then grew by 25.84% to $22.5 million in 2022, then plummeted by 97.78% to $500000.0 in 2023, then skyrocketed by 2580.0% to $13.4 million in 2024, then skyrocketed by 360.63% to $61.7 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Non-Current Assets are $61.7 million (Q4 2025), $45.0 million (Q3 2025), and $29.9 million (Q2 2025).